UNSPSC 51151614: Homatropine hydrobromide

This classification denotes an antimuscarinic agent with the molecular formula C16H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8QS6WCL55Z, chemically known as 1-alpha-h,5-alpha-h-tropan-3-alpha-ol, mandelate (ester) but generally known as homatropine, which bears US NIH Compound Identifier 3623. European Medicines Agency schedules Homatropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02529MIG.

UNSPSC 51151614 Homatropine hydrobromide is a Commodity code for a specific ophthalmic anticholinergic agent, though state and local procurement activity under this code centers on generic multi-source pharmaceutical contracting rather than the procurement of homatropine hydrobromide as a standalone line item. State and local governments buy pharmaceuticals through cooperative purchasing agreements that bundle large classes of drugs—including generics and over-the-counter products—under master vendor contracts that supply health departments, correctional facilities, schools, transit authorities, and other public agencies through authorized wholesale distributors. The issuing bodies are primarily state procurement offices and multistate cooperative purchasing alliances administering pharmaceutical frameworks on behalf of member jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities, including Oregon. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC—and mandates compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Pricing is weighted at 75 percent of the evaluation score, with smaller weights assigned to fixed pricing (10 percent), price competitiveness (5 percent), EDI capability (5 percent), and administrative fee compliance (5 percent). Contract awards are effective July 1, 2026, with a two-year initial term for new vendors and optional extensions at MMCAP's discretion. No specific set-aside designations were identified in the available documentation.